What will Jimenez and the new structure bring to Novartis?
This article was originally published in Scrip
Executive Summary
Change at the top of Novartis has been on the cards for a while. The company had been expected to separate the roles of chairman and CEO, and Daniel Vasella, who has been at the helm for 14 years, was expected to step aside. These changes are now in place, along with some surprises at the top.